Sanofi: more positive results for Dupixent

(CercleFinance.com) - Additional positive results were presented in part A of a pivotal phase III trial evaluating the investigational use of Dupixent (dupilumab) for the treatment of eosinophilic esophagitis in patients aged 12 years and older.


The trial met its primary composite endpoint, as well as all of its secondary endpoints.

Recent new data shows further improvements in the severity and extent of the disease at the microscopic level, as well as normalisation of the expression of genes associated with type-2 inflammation.

"The results from this trial show dupilumab significantly improved both patients' ability to swallow as well as structural abnormalities in the esophagus, by targeting type 2 inflammation to help reverse tissue damage and scarring that usually worsens over time," said Evan S. Dellon, M.D., M.P.H., Professor of Gastroenterology and Hepatology at the University of North Carolina School of Medicine and principal investigator of the trial.


Copyright (c) 2020 CercleFinance.com. All rights reserved.